New cancer clinical trial: Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

Published on: March 29, 2018 at 12:00PM
Conditions:   Melanoma;   Colon Cancer;   Gastrointestinal Cancer;   Genitourinary Cancer;   Hepatocellular Cancer
Intervention:   Biological: NCI-4650, a mRNA-based, Personalized Cancer Vaccine
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting
https://ift.tt/2IiZuYy